GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

LIPO-102

Company
Neothetics, Inc
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00918606

    An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

    Not yet reported Neothetics, Inc 30 participants Est. completion 2009-06 1 site Stand-alone
    Other conditions: Subcutaneous Adipose Tissue Reduction
    View official trial listing →
  • Completed NCT NCT00918814

    Dose Ranging and Dose Frequency of LIPO-102

    Not yet reported Neothetics, Inc 54 participants Est. completion 2010-02 2 sites Stand-alone
    Other conditions: Subcutaneous Adipose Tissue Reduction
    View official trial listing →
  • Completed NCT NCT00954057

    Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)

    Not yet reported Neothetics, Inc 11 participants Est. completion 2011-06 5 sites Stand-alone
    Other conditions: Thyroid-Related Eye Disease
    View official trial listing →
  • Completed NCT NCT01096979

    An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity

    Not yet reported Neothetics, Inc 60 participants Est. completion 2010-03 2 sites Stand-alone
    Other conditions: Subcutaneous Abdominal Adiposity
    View official trial listing →
  • Completed NCT NCT01180465

    A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

    Not yet reported Neothetics, Inc 160 participants Est. completion 2010-09 2 sites Stand-alone
    Other conditions: Weight
    View official trial listing →
  • Completed NCT NCT01712451

    Dose-ranging Study

    Not yet reported Neothetics, Inc 200 participants Est. completion 2012-10 6 sites Stand-alone
    Other conditions: Abdominal Contour Defects
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.